Amneal Pharmaceuticals Inc (NASDAQ: AMRX)’s stock price has plunge by -1.15relation to previous closing price of 7.86. Nevertheless, the company has seen a 14.10% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-09 that Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2024 Earnings Conference Call August 9, 2024 8:30 AM ET Company Participants Tony DiMeo – Head of Investor Relations Chirag Patel – President & Co-Chief Executive Officer Chintu Patel – Co-Chief Executive Officer Tasos Konidaris – Executive Vice President & Chief Financial Officer Joe Renda – Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem – Piper Sandler Leszek Sulewski – Truist Securities Operator Good morning and welcome to the Amneal Pharmaceuticals Second Quarter 2024 Earnings Call. I’d now like to turn the call over to Amneal’s Head of Investor Relations, Tony DiMeo.
Is It Worth Investing in Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Right Now?
Company’s 36-month beta value is 1.16.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AMRX is 119.14M, and currently, short sellers hold a 3.73% ratio of that floaft. The average trading volume of AMRX on August 14, 2024 was 1.45M shares.
AMRX’s Market Performance
AMRX stock saw an increase of 14.10% in the past week, with a monthly gain of 2.24% and a quarterly increase of 13.43%. The volatility ratio for the week is 7.06%, and the volatility levels for the last 30 days are 4.59% for Amneal Pharmaceuticals Inc (AMRX). The simple moving average for the past 20 days is 6.17% for AMRX’s stock, with a 32.02% simple moving average for the past 200 days.
Analysts’ Opinion of AMRX
Many brokerage firms have already submitted their reports for AMRX stocks, with RBC Capital Mkts repeating the rating for AMRX by listing it as a “Sector Perform.” The predicted price for AMRX in the upcoming period, according to RBC Capital Mkts is $5 based on the research report published on April 07, 2021 of the previous year 2021.
Goldman, on the other hand, stated in their research note that they expect to see AMRX reach a price target of $6.50, previously predicting the price at $4. The rating they have provided for AMRX stocks is “Buy” according to the report published on March 08th, 2021.
Guggenheim gave a rating of “Buy” to AMRX, setting the target price at $5.50 in the report published on December 14th of the previous year.
AMRX Trading at 10.85% from the 50-Day Moving Average
After a stumble in the market that brought AMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.66% of loss for the given period.
Volatility was left at 4.59%, however, over the last 30 days, the volatility rate increased by 7.06%, as shares surge +4.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.47% upper at present.
During the last 5 trading sessions, AMRX rose by +14.02%, which changed the moving average for the period of 200-days by +102.74% in comparison to the 20-day moving average, which settled at $7.34. In addition, Amneal Pharmaceuticals Inc saw 28.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMRX starting from Shah Nikita, who proposed sale 30,000 shares at the price of $7.86 back on Aug 14 ’24. After this action, Shah Nikita now owns shares of Amneal Pharmaceuticals Inc, valued at $235,800 using the latest closing price.
Autor Deborah M., the Director of Amneal Pharmaceuticals Inc, sale 23,447 shares at $6.73 during a trade that took place back on May 17 ’24, which means that Autor Deborah M. is holding 93,402 shares at $157,728 based on the most recent closing price.
Stock Fundamentals for AMRX
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.35 for the gross margin
The net margin for Amneal Pharmaceuticals Inc stands at -0.06. The total capital return value is set at 0.07. Equity return is now at value -133.96, with -4.84 for asset returns.
Based on Amneal Pharmaceuticals Inc (AMRX), the company’s capital structure generated 1.02 points at debt to capital in total, while cash flow to debt ratio is standing at 0.08. The debt to equity ratio resting at -44.31. The interest coverage ratio of the stock is -8.33.
Currently, EBITDA for the company is 417.96 million with net debt to EBITDA at 9.23. When we switch over and look at the enterprise to sales, we see a ratio of 1.89. The receivables turnover for the company is 3.37for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.33.
Conclusion
In a nutshell, Amneal Pharmaceuticals Inc (AMRX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
